Our group at the Phagocyte Laboratory (Sanquin Research) of the Landsteiner Laboratory is interested in antibody immunotherapy against cancer. The major aim is to improve treatment of cancer patients with therapeutic antibodies in order to reduce the need for non-specific agents, such as chemotherapeutics. We have identified CD47-SIRPalpha interactions as an innate immune checkpoint during antibody therapy in cancer. Work is ongoing to explore the mechanisms of antibody-dependent cancer cell destruction by human innate immune cells and the ways in which this can be further improved. We are also interested in the role of innate immune cells in other diseases, including primary immunodeficiencies. In that context the Phagocyte Laboratory also provides a specialized diagnostic service for phagocyte functional and genetic defects.
Kuijpers TW, Tool ATJ, van der Bijl I, de Boer M, van Houdt M, de Cuyper IM, Roos D, van Alphen F, van Leeuwen K, Cambridge EL, Arends MJ, Dougan G, Clare S, Ramirez-Solis R, Pals ST, Adams DJ, Meijer AB, van den Berg TK. Combined immunodeficiency with severe inflammation and allergy caused by ARPC1B deficiency. J ALLERGY CLIN IMMUN 2017;140 (1):273-+
van den Berg TK, van Bruggen R. Loss of CD47 Makes Dendritic Cells See Red. IMMUNITY 2015;43 (4):622-624
Szilagyi K, Gazendam RP, van Hamme JL, Tool ATJ, van Houdt M, Vos WAJW, Verkuijlen P, Janssen H, Belot A, Juillard L, Förster-Waldl E, Boztug K, Kraal G, de Winther MPJ, Kuijpers TW, van den Berg TK. Impaired microbial killing by neutrophils from patients with protein kinase C delta deficiency. J ALLERGY CLIN IMMUN 2015;136 (5):1404-7.e1-10
Barclay AN, van den Berg TK. The interaction between signal regulatory protein alpha (SIRPa) and CD47: structure, function, and therapeutic target. ANNU REV IMMUNOL 2014;32:25-50
Zhao XW, van Beek EM, Schornagel K, van der Maaden H, van Houdt M, Otten MA, Finetti P, van Egmond M, Matozaki T, Kraal G, Birnbaum D, van Elsas A, Kuijpers TW, Bertucci F, van den Berg TK. CD47-signal regulatory protein-a (SIRPa) interactions form a barrier for antibody-mediated tumor cell destruction. P NATL ACAD SCI USA 2011;108 (45):18342-18347